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The atypical PKC isoforms (ζ and ι) play essential roles in regulating various cellular processes. Both the hetero-interaction 
between PKCζ and p62 through their N-terminal PB1 domains and the homo-oligomerization of p62 via its PB1 domain are 
critical for the activation of NF-B signaling; however, the molecular mechanisms concerning the formation and regulation of 
these homotypic complexes remain unclear. Here we determined the crystal structure of PKCζ-PB1 in complex with a mono-
meric p62-PB1 mutant, where the massive electrostatic interactions between the acidic OPCA motif of PKCζ-PB1 and the 
basic surface of p62-PB1, as well as additional hydrogen bonds, ensure the formation of a stable and specific complex. The 
PKCζ-p62 interaction is interfered with the modification of a specific Cys of PKCζ by the antiarthritis drug aurothiomalate, 
though all four cysteine residues in the PKCζ-PB1 domain can be modified in in vitro assay. In addition, detailed structural and 
biochemical analyses demonstrate that the PB1 domains of aPKCs belong to the type I group, which can depolymerize the 
high-molecular-weight p62 aggregates into homo-oligomers of lower order. These data together unravel the molecular mecha-
nisms of the homo- or hetero-interactions between p62 and PKCζ and provide the basis for designing inhibitors of NF-B sig-
naling. 
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The protein kinase C (PKC) family comprises a number of 
highly related serine/threonine kinases in mammals, which 
exert pivotal roles in many cellular processes and have been 
the focus of drug development in cancer, diabetic complica-
tions, heart failure and many other diseases [1–3]. Based on 
their cofactor requirements and sequence homology, these 
important kinases can be classified in three subfamilies: 
conventional (cPKC: α, β and γ), novel (nPKC: δ, ε, η and 
θ), and atypical (aPKC: ζ and ι/λ) [4]. The cPKCs are acti-
vated by both diacylglycerol (DAG) and Ca2+, and each 
cPKC consists of an N-terminal autoinhibitory pseudosub-
strate motif, a DAG binding C1 domain and a Ca2+ sensing 
C2 domain followed by the catalytic kinase domain. The 
nPKCs resemble the cPKCs but are only activated by DAG 
because their C2 domains do not bind Ca2+. The aPKC sub-
family is unresponsive to both DAG and Ca2+ due to the 
presence of an incomplete C1 domain and the lack of a C2 
domain. Instead, the aPKCs are regulated by the PB1 (Phox 
and Bem1p) domain at their N-termini (Figure 1A), which 
is one of the protein-interacting modules that undergo ho-
motypic domain-domain interactions and thus mediate a 
number of cellular signaling pathways [5–8]. 
The aPKC isoforms have been implicated in the regula-
tion of many important signaling pathways such as NF-B 
signaling, cell polarity pathway and MAPK/ERK cascade, 
where the PB1-mediated interactions between aPKCs and 
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their interacting proteins including p62, Par-6 and MEK5 
are essential for the biological functions of aPKCs [9,10]. 
The scaffold protein p62 is one of the well-characterized 
aPKC-interacting proteins, which is rich in protein-     
interacting domains/motifs consistent with its essential roles 
as a signaling hub in modulating cell survival, apoptosis, 
adipogenesis and autophagy [11–14]. The p62 protein also 
harbors an N-terminal PB1 domain (Figure 1A), and the 
PB1-PB1 interaction between aPKC and p62 ensures speci-
ficity and fidelity in the activation of NF-B [15–17]. In 
addition, the PB1 domain of p62 facilitates its ho-
mo-oligomerization, which is also critical for its biological 
functions [18,19]. For instance, the PB1-mediated ho-
mo-oligomerization of p62, as well as its interaction with 
TRAF6 through the TRAF6-binding sequence, is required 
for the formation of p62-TRAF6 signaling hubs, the 
polyubiquitination of TRAF6 and the ultimate activation of 
NF-B [20,21]. 
Although the significance of the PB1-containing proteins, 
aPKCs and p62, in the regulation of NF-B signaling and 
many cellular pathways has been well acknowledged, the 
molecular mechanism of homo- and/or hetero-interactions 
between two PB1 domains and its biological implication are 
elusive. In this study, we determined the complex structure 
of the PB1 domains of p62 and the atypical PKCζ. Although 
the interaction between PKCζ-PB1 and p62-PB1 obeys the 
general property of PB1-PB1 interaction, our structure re-
veals an additional interacting site that ensures the specific 
recognition of p62 by PKCζ. PKCζ depolymerizes p62 ho-
mo-oligomer by competing for the basic surface on the 
p62-PB1 domain that mediates self-association of p62. In 
addition, we found that the antirheumatoid gold compound 
aurothiomalate (ATM) can modify all four solvent-accessi- 
ble thiol groups of PKCζ-PB1, among which only Cys68 is 
located at the interface. Our biochemical analyses demon-
strate that the ATM modification of Cys68 impedes the in-
teraction between PKCζ-PB1 and p62-PB1, which sheds 
light on the molecular mechanism of ATM in the cure of 
rheumatoid arthritis, a chronic inflammatory disease associ-
ated with NF-B activation. 
1  Materials and methods 
1.1  Constructs, mutagenesis, and protein purification 
Plasmids of rat PKCζ and human p62 were kindly provided 
by Dr. Wang HongRui (Xiamen University). The PB1 do-
mains of PKCζ (residues 12–101) and p62 (residues 1–102) 
were generated by standard PCR procedure and inserted 
into pACYCDuet-1 or pGEX-4T-2 vectors with N-terminal 
His6 or GST tag. The site-specific mutations of the PB1 
domains were generated by PCR based site-directed muta-
genesis and verified by sequencing. All proteins, overex-
pressed in E. coli BL21 (DE3) at 20°C, were purified at 4°C 
over affinity columns (glutathione-Sepharose 4B, GE 
Healthcare, Pittsburgh, USA or Ni-NTA, Qiagen,Valencia, 
USA) and anion exchange columns (DEAE FF or Source 
15Q, GE Healthcare), followed by size exclusion chroma-
tography (Superdex 200, GE Healthcare). The PB1 com-
plexes for crystallization trials were prepared by coexpres-
sion of GST-PKCζ-PB1 and His6-p62-PB1AM, and the 
GST tag was removed using human rhinovirus 3C protease 
before the ion exchange chromatography. All proteins were 
stored at −80°C. 
1.2  Plasmids, cell culture, transfection, and co-immuno- 
precipitation 
The pCMV-Myc-PKCζ, pCS2+-Flag-p62 and their muta-
tion/deletion constructs were generated according to stand-
ard molecular techniques, and the authenticities were con-
firmed by sequencing. HEK293T cells were maintained in 
DMEM medium (Invitrogen, Grand Island, USA) supple-
mented with 10% fetal bovine serum (HyClone, Waltham, 
USA), 100 µg mL1 penicillin and 100 µg mL1 streptomy-
cin (Sigma-Aldrich, St. Louis, USA). Each indicated DNA 
was transfected into HEK293T cells seeded in a 35-mm 
dish, using VigoFect (Vigorous, Beijing, China) according 
to the manufacturer’s instructions. After 24 h, cells were 
lysed in the lysis buffer containing 20 mmol L1 Tris (pH 
7.4), 150 mmol L1 NaCl, 0.5% NP-40, 25 mmol L1 NaF, 2 
mmol L1 Na3VO4, 1 mmol L1 EDTA, 1 mmol L1 PMSF 
and one protease inhibitor cocktail tablet (Roche, Indianap-
olis, USA) per 50 mL. The lysates were incubated at 4°C 
for 10 min and then centrifuged at 13000 r min1 for 10 min. 
The supernatants were immunoprecipitated with indicated 
antibody and protein A/G plus agarose (Santa Cruz Bio-
technology, Dallas, USA) and rotated overnight at 4°C. Af-
ter spinning and washing for three times with the lysis buff-
er, the beads were mixed with SDS loading buffer, boiled, 
and subjected to SDS-PAGE. The samples were transferred 
to PVDF membranes (Millipore, Billerica, USA) and im-
munoblotted using anti-Myc (Santa Cruz Biotechnology) 
and anti-Flag (Sigma-Aldrich) antibodies, respectively. 
1.3  Gel filtration analysis 
Size exclusion chromatography using the Superdex 200 
10/300 column on an ÄKTA FPLC (GE Healthcare) was 
carried out at 4°C to assess the apparent molecular weight 
of wild-type p62-PB1 and its mutants in solution and the 
interactions between p62-PB1 and PKCζ-PB1. The column 
was equilibrated with a buffer containing 50 mmol L1 Tris 
(pH 8.0), 150 mmol L1 NaCl at a flow rate of 0.5 mL min1 
and calibrated with molecular mass standards. All protein 
samples or mixtures were diluted with the equilibration 
buffer to indicated concentrations and incubated on ice for  
1 h to allow equilibrium to be reached. Each sample at a 
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volume of 500 µL was loaded to the Superdex column, and 
fractions of 0.5 mL each were collected. Aliquots of rele-
vant fractions were subjected to SDS-PAGE, and proteins 
were visualized by Coomassie Blue staining. 
1.4  Crystallization, data collection, and structure de-
termination 
Crystals of the complex between p62-PB1AM and 
PKCζ-PB1 were grown using the hanging drop vapor diffu-
sion method by mixing 2 µL of the protein (~10 mg mL1) 
with 1 µL of reservoir solution containing 0.1 mol L1 Tris 
(pH 8.5), 8% PEG 8000, 0.4 mol L1 MgCl2, and 0.05 mol 
L1 potassium sodium tartrate at 21°C. Crystals were 
quickly transferred to a cryo-protectant buffer containing 
the reservoir solution supplemented with 20% (v/v) eth-
ylene glycol and then flash-frozen under cold nitrogen 
stream at 100 K. The diffraction data were collected at 
beamline 17U at Shanghai Synchrotron Radiation Facility 
and processed by the HKL-2000 package [22]. The struc-
ture was solved by molecular replacement using Phaser [23] 
with the structure of PKCι-Par6α PB1 complex (PDB ID: 
1WMH) [24] as the search model. Standard refinement was 
performed with PHENIX [25] and Coot [26], and 
PROCHECK [27] was used to check the structure stereo-
chemistry. The data processing and refinement statistics are 
summarized in Table 1, and the atomic coordinates and 
structure factors have been deposited in the PDB 
(http://www.pdb.org) under the accession code 4MJS. All 
structural representations in this paper were prepared with 
PyMOL (http://www.pymol.org). 
1.5  GST-mediated pull-down assay 
The recombinant GST-tagged PKCζ-PB1 protein (~0.4 mg) 
was bound to glutathione-Sepharose 4B resin (0.2 mL) 
pre-equilibrated with the buffer containing 50 mmol L1 
Tris (pH 8.0) and 150 mmol L1 NaCl. To remove excess 
unbound GST-PKCζ-PB1 or other contaminants, the resin 
was washed three times with 1 mL buffer. Then, ~0.4 mg of 
His6-tagged p62-PB1 was allowed to flow through the 
PKCζ-PB1-bound resin. After extensive washing, the bound 
proteins were eluted with 10 mmol L1 reduced glutathione. 
All samples were subjected to SDS-PAGE, and proteins 
were visualized by Coomassie Blue staining. 
1.6  Modification of cysteine 
The recombinant PKCζ-PB1 protein was mixed with 
10-fold ATM in a buffer containing 50 mmol L1 Tris (pH 
7.4) and 150 mmol L1 NaCl, and the mixture was incubat-
ed at 30°C for 15 min. Excess ATM was removed by gel 
filtration. Both native and ATM-modified PKCζ-PB1 were 
subjected to modification by another thiol-reactive com-
pound, the Ellman’s reagent DTNB (5,5′-Dithiobis-(2-nitro- 
benzoic acid)). 
Modification of the free thiol groups of PKCζ-PB1 by 
DTNB was carried out at 30°C in 1.8 mL reaction mixture 
containing 50 mmol L1 Tris (pH 8.1), 150 mmol L1 NaCl, 
0.1 mmol L1 EDTA and indicated amounts of DTNB and 
PKCζ-PB1. Reactions were initiated by the addition of the 
PKCζ-PB1 protein to the reaction mixture. Progress of the 
reaction was monitored continuously by following the gen-
eration of 2-mercapto-5-nitrobenzoic acid (TNB2) at   
412 nm on a Lambda 45 spectrophotometer (PerkinElmer, 
Waltham, USA) equipped with a magnetic stirrer in the cu-
vette holder. The concentrations of available cysteine resi-
dues were calculated using an extinction coefficient for 
TNB2 of 14140 cm1 M1 at 412 nm [28]. 
1.7  Isothermal titration calorimetry 
To assess the binding affinity between PKCζ and p62, we 
titrated p62-PB1AM into PKCζ-PB1 using ITC carried out 
at 25°C on a VP-ITC MicroCalorimeter (GE Healthcare). 
All proteins were prepared in a buffer containing 25 mmol 
L1 Hepes (pH 7.4) and 150 mmol L1 NaCl. The sample 
cell was loaded with 1.43 mL of PKCζ-PB1 (5 µmol L1), 
and titration was carried out using a 284-µL syringe filled 
with p62-PB1AM (50 µmol L1). Each titration experiment 
consisted of 27 consecutive injections of 10-µL volume and 
20-s duration each, with a 5-min interval between injections. 
To correct for the heat effects of dilution and mixing, con-
trol experiments were performed in which p62-PB1AM was 
injected into an identical solution but without PKCζ-PB1. 
To determine the binding affinity between two p62-PB1 
domains, the p62-PB1BM mutant (7 µmol L1) was similar-
ly titrated with p62-PB1AM (50 µmol L1). The calorimetric 
data were analyzed with a one-site binding model assuming 
a binding stoichiometry of 1:1 using ORIGIN software 
supplied with the instrument. 
2  Results and discussion 
2.1  Both PB1 domains are indispensable for the inter-
action between p62 and PKCζ 
Both PKCζ and p62 are multidomain proteins, each con-
taining a PB1 domain (Figure 1). To verify the p62-PKCζ 
interaction, we first performed co-immunoprecipitation as-
says using ectopically expressed proteins. As shown in Fig-
ure 2A, the full-length PKCζ protein was co-immunopre- 
cipitated by the full-length p62, whereas deletion of the PB1 
domain of either PKCζ or p62 resulted in failure to bind to 
the counterpart protein. These data suggest that the PB1 
domains are indispensable for the p62-PKCζ interaction. 
Then, we analyzed the direct interaction between the puri-
fied recombinant proteins of the isolated PB1 domains using 
gel filtration assays (Figure 2B and C). The PB1 domains, 
each consisting of approximate 80 residues, are conserved  
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Figure 1  Functional domains/motifs of PKCζ and p62. A, Schematic diagrams of rat PKCζ (Swiss-Prot ID: P09217) and human p62 (Q13501). PS, pseu-
dosubstrate; KD, kinase domain; ZZ, ZZ-type zinc finger domain; TBS, TRAF6-binding sequence; UBA, ubiquitin associated domain. B, Sequence align-
ment of the PB1 domains of representative PB1-containing proteins from human and rat. The code following each protein name is the corresponding 
Swiss-Prot ID, and secondary structural elements of rat PKCζ-PB1 (green) and human p62-PB1 (cyan) are indicated above their sequences, respectively. The 
key residues at sites A1, A2 and A3 of PKCζ-PB1 are indicated by red asterisks, squares and triangles, respectively, and the interacting residues at sites B1, 
B2 and B3 of p62-PB1 are indicated by corresponding blue symbols. The OPCA motif conserved among type I and I/II PB1 domains and the cysteine resi-
dues of aPKCs are boxed, and the essential Cys within the OPCA motif is also indicated by orange diamond. 
among fungi, plants and animals and can be grouped into-
three types: type I, type II, and type I/II (Figures 1B) [29]. 
The type I group contains a conserved acidic motif (named 
the OPCA motif), while the type II group contains several 
lysine and/or arginine residues that form a basic surface 
opposite to the OPCA motif [10,30]. Therefore, the type I 
and type II PB1 domains can form heterodimers via electro-
static interactions [24,31,32]. The type I/II group contains 
both the OPCA motif and the basic surface, which enable 
the formation of homo-oligomers [8,33]. The PB1 domain 
of p62 (p62-PB1, residues 1–102) belongs to type I/II, and 
the wild-type recombinant p62-PB1 proteins indeed behave 
as high-molecular-weight aggregates, which makes the pro-
tein purification difficult (Figure 2B). Mutation of the high-
ly conserved residues in the acidic motif (D69A/D71R, 
hereafter referred to as p62-PB1AM) or on the basic surface 
(p62-PB1BM, K7E/R96A) resulted in two monomeric 
p62-PB1 mutants [34]. When the p62-PB1AM mutant was 
mixed with equimolar amount of the PB1 domain from 
PKCζ (PKCζ-PB1, residues 12–101), the vast majority of 
these two PB1 proteins co-migrated in earlier fractions, in-
dicating the formation of a stable complex with 1:1 stoi-
chiometry (Figure 2C). By contrast, the p62-PB1BM mutant 
does not interact with PKCζ-PB1 as reported [35]. We also 
examined the effect of the p62AM mutation on the interac-
tion between two full-length proteins using the co-      
immunoprecipitation assay, and the result reaffirms that the 
p62AM mutant, engineered to destroy the acidic OPCA 
motif, does not abolish the binding of p62 to PKCζ (Figure 
2A). Together, these results demonstrate that the N-terminal 
PB1 domains are necessary and sufficient for the p62-PKCζ 
interaction and that p62-PB1 provides the basic surface to 
interact with the acidic OPCA motif of PKCζ-PB1. 
2.2  Overall structure of a heterodimeric complex be-
tween PKCζ-PB1 and p62-PB1AM 
To unravel the molecular mechanism of the aPKC-p62 in-
teraction, we carried out crystallization trials for complexes  
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Figure 2  PKCζ interacts with p62 through their PB1 domains. A, 
Co-immunoprecipitation (IP) assays for the interaction between PKCζ and 
p62. HEK293T cells were co-transfected with 2 µg of Myc-PKCζ and 1 µg 
of Flag-p62 plasmids as indicated. Lysates were subjected to anti-Flag 
immunoprecipitation followed by anti-Myc immunoblotting (IB). B, Oli-
gomerization states of PKCζ-PB1 and wild-type or mutant p62-PB1. The 
size exclusion chromatography was performed to determine the apparent 
molecular weight of the PB1 domain/mutant at a concentration of ~10 
µmol L1. C, PKCζ-PB1 binds to the p62-PB1AM mutant with intact basic 
surface. PKCζ-PB1 (50 µmol L1) was incubated with indicated p62-   
PB1 mutant (50 µmol L1), and the mixture was subjected to gel filtration 
analysis. 
between PKCζ-PB1 and p62-PB1. We purified the 
wild-type PB1 complex by coexpression of wild-type 
PKCζ-PB1 and p62-PB1 in E. coli; however, all attempts to 
crystallize the wild-type complex were unsuccessful, likely 
due to heterogeneity of the p62 homo-oligomers. We turned 
to solve the structure of the 1:1 complex between PKCζ-  
Table 1  Data collection and refinement statistics 
 PKC-p62 PB1 complex 
Data collectiona)  
Space group P212121 
Cell dimensions  
    a, b, c (Å) 85.72, 135.68, 259.56 
    , ,  () 90, 90, 90 
Resolution (Å) 40.002.50 (2.592.50)b) 
Rmerge 0.086 (0.519) 
I/(I) 22.6 (4.1) 
Completeness (%) 100.0 (100.0) 
Redundancy 7.3 (7.5) 
Refinement  
Resolution (Å) 39.532.50 
No. reflections 105316 
Rwork/Rfree
c) 23.8/28.7 
No. atoms  
    Protein 16410 
    Solvent 397 
B-factors (Å2)  
    Protein 52.55 
    Solvent 39.49 
r.m.s. deviations  
    Bond lengths (Å) 0.009 
    Bond angles (º) 1.200 
Ramachandran plot  
Most favored 1633 (92.6%) 
Additionally allowed 128 (7.3%) 
Generously allowed 3 (0.2%) 
Disallowed 0 (0.0%) 
a) All data sets were collected from a single crystal. b) Values in pa-
rentheses are for the highest resolution shell. c) Rfree was calculated on a 
random 5.0% reflections of the data. 
PB1 and the p62-PB1AM mutant. Fortunately, we generat-
ed diffractable crystals and determined the complex struc-
ture to a resolution of 2.5 Å (Figure 3A, Table 1). The crys-
tal belongs to space group P212121, and each asymmetric 
unit contains 12 identical p62-PKCζ heterodimers. Both 
PKCζ-PB1 and p62-PB1 in the complex structure display 
essentially the same topology as other PB1 domains, a 
ubiquitin-like β-grasp fold composed of one five-stranded 
β-sheet (β1-β5) and two α-helices [24,29,30,32,33,35,36]. 
The basic surface is mainly formed by the β1-β2 hairpin at 
the ‘front’ of the PB1 domain, whereas the acidic OPCA 
motif folds into the β3-β4 hairpin and helix α2 at the ‘back’ 
opposite to the basic side. The basic surface of p62-PB1 
indeed interacts with the acidic OPCA motif of PKCζ-PB1 
in a front-to-back manner, resulting in the burial of ap-
proximate 1100 Å2 exposed surface area (Figure 3A). 
The structures of these two PB1 domains are readily su-
perimposable to each other with an overall root-mean- 
square deviation of approximate 1.6 Å over 60 core Cα at-
oms, and the major structural deviations were mapped to the 
α2 helix and some loop regions (Figure 3B). The NMR 
structures of the isolated PB1 domains of p62 (p62-PB1AM; 
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Figure 3  Crystal structure of p62-PKCζ PB1 complex. A, Schematic representations of the complex between p62-PB1 (cyan) and PKCζ-PB1 (green) in 
two views related by a 90° rotation around a horizontal axis. In the left panel, the interfaces on p62-PB1 and PKCζ-PB1 are circled in blue and red, respec-
tively. In the right panel, all four Cys residues within PKCζ-PB1 are shown in yellow spheres. B, Superposition of p62-PB1 (cyan) and PKCζ-PB1 (green) in 
the complex. C, Superposition of p62-PB1 (cyan) and the isolated p62-PB1 (blue, PDB ID: 2KKC). D, Superposition of PKCζ-PB1 (green) and the isolated 
PKCι-PB1 (salmon, PDB ID: 1VD2). 
PDB ID: 2KKC) and the other aPKC (PKCι-PB1; PDB ID: 
1VD2) have been determined [33,35], and we respectively 
superimposed the p62-PB1 and PKCζ-PB1 domains in our 
complex with these reported structures (Figure 3C and D). 
Their main chains exhibit little conformational differences, 
except some loop regions. However, the side chain of 
Arg21 on strand β2 of p62-PB1 rotates approximately 45° 
(Figure 3C), and Glu64 at the β3-β4 loop of PKCζ-PB1 
(corresponding to Glu65 of PKCι-PB1) shifts ~4 Å and ro-
tates ~45° (Figure 3D). In fact, upon the hetero-complex 
formation, many residues that are critical to the interactions 
between the p62-PB1 and aPKC-PB1 domains (see below) 
undergo subtle or even dramatic conformational changes. 
2.3  The electrostatic interactions play a dominant role 
in p62-PKCζ complex formation 
A close-up view of the intermolecular interface of the 
p62-PKCζ complex reveals that the interaction pattern re-
sembles a three-pin plug, three functional clusters (A1A3) 
within the OPCA motif of PKCζ-PB1 interacting with three 
basic or hydrophilic regions (B1B3) on the opposite sur-
face of p62-PB1, respectively (Figure 4A). The most acidic 
A1 site of PKCζ-PB1 is located at the β3-β4 hairpin, pre-
senting three acidic residues Asp62, Glu64 and Asp66 (Fig-
ure 4B). This highly negative charged area is in close 
proximity to the prominent basic patch B1 of p62-PB1, 
which contains three positively charged side chains of Lys7, 
Arg22 and Arg96 from strands β1, β2 and β5. A total of six 
salt bridges are formed between the complementary A1 and 
B1 patches, which constitute the major interactions between 
PKCζ-PB1 and p62-PB1. Specifically, Lys7 of p62-PB1, 
the most conserved and representative residue on the basic 
surface of type II and type I/II PB1 domains, forms three 
salt bridges with all of the three acidic residues at the A1 
site of PKCζ-PB1, and Arg22 and Arg96 in p62-PB1 re-
spectively interact with Asp62 and Glu64 in PKCζ-PB1. 
The β2 strand of p62-PB1 contains two consecutive Arg 
residues (Figure 1B), where the side chain of Arg21 points 
to the opposite direction of Arg22 at site B1 and forms an 
additional positive electrostatic patch, B2 (Figure 4A and C). 
In PKCζ-PB1, the A2 site consists of Ser71 and Glu75 at 
the β4-α2 loop and the N-terminal turn of helix α2, and both 
side chains interact with Arg21 of p62-PB1. At the A3-B3 
interface, Thr5 and Ser24 from strands β1 and β2 of 
p62-PB1 (B3) respectively form hydrogen bonds to Arg81 
and Glu78 on helix α2 of PKCζ-PB1 (A3), and the two 
PKCζ residues form two additional intramolecular salt 
bridges, further stabilizing this interface (Figure 4D). To-
gether, the electrostatic and hydrogen bond interactions at 
three paired sites of A1-B1, A2-B2 and A3-B3 within their 
PB1 domains lead to the formation of stable p62-PKCζ 
complex. Structural inspections of the reported PB1 homo- 
and hetero-dimers demonstrated that some cognate pairs 
display auxiliary interactions in addition to the conserved 
A1-B1 and A2-B2 sites [24,32]. Based on sequence analysis 
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(Figure 1B), we believe that this additional A3-B3 interface 
plays a crucial role in the specific recognition between p62 
and aPKCs. 
To complement the structure analyses, we first generated 
a series of point mutations on PKCζ-PB1 and examined 
their effect on the formation of p62-PKCζ complex using 
GST-mediated pull-down assays. When p62-PB1AM was 
applied to the wild-type GST-PKCζ-PB1 preimmobilized to 
glutathione resin (Figure 4E, lane 1), these two PB1 do-
mains formed a stable hetero-complex as resolved by 
SDS-PAGE. When the important acidic residues at sites A1 
and A2 of PKCζ-PB1 were individually replaced by Ala, the 
resulting PKCζ mutants (D62A, E64A, D66A and E75A) 
drastically abrogated the binding to p62-PB1AM (Figure 
4E). By contrast, mutations of Ser71 at site A2 and both 
residues at site A3 displayed little effect on the het-
ero-complex formation. Residue Trp60 within the OPCA 
motif of PKCζ-PB1 had been shown to mediate the homo-
typic PB1-PB1 interaction [18]. Although this residue is not 
directly involved in the PB1 complex formation, it partici-
pates in the hydrophobic core formation of the PB1 domain. 
Indeed, the W60A mutant impaired the interaction with 
p62-PB1, most likely due to disturbance of the integrity of 
PB1 domain (Figure 4E, lane 2). We next mutated the key 
interacting residues on the basic surface of PKCζ-PB1AM 
and carried out pull-down assays with wild-type GST- 
PKCζ-PB1 (Figure 4F). Substitutions of the basic residues 
Lys7, Arg21, Arg22 and Arg96 at both sites B1 and B2 of 
 
 
Figure 4  Interactions between p62-PB1 and PKCζ-PB1. A, Surface representations of p62-PB1 (left) and PKCζ-PB1 (right) showing their interfaces. The 
two surface representations, colored according to electrostatic potential (positive, blue; negative, red), are respectively oriented by a 90° rotation around a 
vertical axis as indicated. BD, Close-up views of interactions at the B1:A1 (B), B2:A2 (C) and B3:A3 (D) interfaces. The interacting residues of p62-PB1 
and PKCζ-PB1 are highlighted as orange and magenta sticks, respectively. Ion-pair and hydrogen-bonding interactions are indicated by black dashed lines. E 
and F, Effect of the point mutations of interacting residues on PKCζ-PB1 (E) or p62-PB1 (F) on the formation of PKCζ-p62 complex. In the GST-mediated 
pull-down assay, the glutathione beads immobilized with GST-PKCζ-PB1 were used to pull down p62-PB1. The top panels are the electrophoretic patterns 
after pull-down assays, and protein amounts of the GST-PKCζ-PB1 (E) and p62-PB1 (F) mutants used are shown in the bottom panels, respectively. The 
asterisk indicates the GST contaminant. 
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p62-PB1 completely ablated the formation of hetero-  
complex by disrupting the electrostatic interactions, while 
neither of the mutations at site B3 (T5A and S24A) inter-
fered with its hetero-interaction with PKCζ-PB1. These data 
demonstrate that the electrostatic interactions at the A1-B1 
and A2-B2 interfaces are the major forces in the formation 
of a stable complex between PKCζ-PB1 and p62-PB1, 
while the hydrogen bonds between sites A3 and B3 exert an 
auxiliary function in specific recognition. 
2.4  The aPKC-PB1 domains belong to type I, rather 
than type I/II 
In human genome, there are at least 13 PB1-containing pro-
teins that can form specific homo- or hetero-complexes to 
precisely modulate cellular signaling pathways, and a num-
ber of crystal/NMR structures of the homotypic PB1-PB1 
complexes have been reported [24,32,34]. When these PB1 
complexes were superimposed to our p62-PKCζ complex, 
the relative orientations between two interacting PB1 do-
mains in different complexes may change remarkably (Fig-
ure 5A). The two PB1 domains in the Par-6-PKCι (PDB ID: 
1WMH) or MEKK2-MEK5 (2NPT) heterodimeric struc-
tures adopt almost identical relative positions as that in the 
p62-PKCζ complex, while the relative orientation between 
two p62-PB1 domains in its homodimeric structure (2KTR) 
displays moderate difference. Notably, the relative orienta-
tion in the complex of the p67phox-PB1 and p40phox-PB1 do-
mains (1OEY) seems to be distinct, likely because of the 
additional interactions mediated by the C-terminal tail of 
p40phox-PB1. Nevertheless, all the homo- or hetero-   
complexes are formed in the front-to-back manner through 
interactions between the conserved basic surface and acidic 
OPCA motif. 
Because of the presence of both the OPCA motif and an 
invariant Lys on strand β1, the PB1 domains of aPKCs were 
thought to belong to the type I/II group (Figure 1B). There-
fore, the aPKC-PB1 domains, similar to p62-PB1, were 
expected to mediate homo-oligomerization and/or interact 
with either other type I or type II PB1 domains. Although 
self-assembly has not been shown for the aPKC-PB1 do-
mains, evidences showed that aPKC-PB1 can form complex 
with different types of PB1 domains from MEK5, Par-6 and 
p62-PB1, respectively [18,31,32,35]. However, the PB1 
domains of both PKCζ and PKCι do not form complex with 
the type I MEK5-PB1 in in vitro gel filtration and GST- 
mediated pull-down assays (data not shown), and they in-
teract with the type II Par-6-PB1 and the type I/II p62-PB1  
 
 
Figure 5  aPKC-PB1 belongs to type I. A, Superposition of p62-PKCζ (cyan and green) with Par-6-PKCι (salmon, PDB ID: 1WMH), p62-p62 (blue, 
2KTR), MEKK2-MEK5 (magenta, 2NPT) or p67phox-p40phox (yellow, 1OEY). The PB1 domain in each complex that provides the basic surface for the ho-
motypic interaction is used for superposition. B, Surface representations of the basic surfaces or the corresponding surfaces of indicated PB1 domains ori-
ented the same as p62-PB1 in Figure 4A. The surface representations are colored by electrostatic potential, and the basic residues contributing to the posi-
tively charged regions are indicated. 
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domains in almost identical mode through the acidic OPCA 
motif (Figure 5A). In addition, the sequences of both 
aPKC-PB1 domains are lack of several key basic residues 
that were identified in the reported PB1 complex structures 
(Figure 1B). These analyses indicate that aPKC-PB1 should 
belong to the type I group. On close inspection of the sur-
face potential, we found that all the functional basic surface 
of the type II and type I/II PB1 domains present both the B1 
and B2 sites (Figure 5B). In particular, the B1 site is unam-
biguously centered on the invariant Lys on strand β1, while 
site B2 is formed by Lys or Arg from strand β2 (p62, Par-6 
and MEKK2/3) or helix α1 (p67phox). By contrast, the cor-
responding surfaces on the type I PB1 domains from MEK5 
and p40phox are essentially negatively charged (Figure 5B). 
Remarkably, the corresponding ‘B2 sites’ of two aPKC-PB1 
domains are strikingly acidic, though their ‘B1 sites’ display 
the positive electrostatic patches. Our data (Figure 4F), to-
gether with previous reports, clearly suggest that the B2 site 
is indispensable for the PB1-PB1 homotypic interactions. 
Therefore, we believe that the presence of an acidic ‘B2 
site’ on the basic surface would impede its interaction with 
the acidic OPCA motif, and that the PB1 domains of aPKCs 
should be classified into type I (Figure 1B). 
2.5  Cysteine modification of PKCζ-PB1 by ATM im-
pedes its interaction with p62-PB1 
The gold-containing compounds aurothioglucose (ATG) 
and aurothiomalate (ATM) in active clinical use for the 
treatment of rheumatoid arthritis are thiol-reactive agents 
capable of modifying cysteine residues [37]. These com-
pounds have been shown to effectively modify PKCι and 
ablate its association with Par-6 [38–40]. Considering that 
PKCζ and PKCι are highly conserved in both sequence and 
structure, we examined the effect of ATM modification on 
the interaction between PKCζ and p62. We prepared the 
ATM-modified PKCζ-PB1 protein and assessed the binding 
affinity between p62 and PKCζ using isothermal titration 
calorimetry (ITC). As expected, the native PKCζ-PB1 pro-
tein forms a stable complex with p62-PB1, with a dissocia-
tion constant (Kd) of 21.6±2.09 nmol L
1 that is comparable 
to the reported values for other PB1-PB1 assemblies  
[30,32]. On the contrary, the ATM-modified PKCζ-PB1 
failed to bind to p62-PB1 (Figure 6A), suggesting that ATM 
modifies PKCζ-PB1 and impedes its interaction with 
p62-PB1. 
ATM was suggested to selectively target a unique cyste-
ine residue, Cys69, within the OPCA motif of PKCι-PB1 
[38]. However, there are four cysteine residues in both 
aPKC-PB1 sequences, and these thiol groups are all ex-
posed to solvent in their structures (Figures 1B and 3A). To 
examine whether all Cys residues can be modified, we 
studied the modification kinetics of PKCζ-PB1 by DTNB, a 
widely used reagent that reacts specifically with available 
thiol groups of proteins. Time course for the DTNB modi-
fication of free thiol groups can be monitored spectropho-
tometrically (Figure 6B). When the native PKCζ-PB1 pro-
tein (1 µmol L1) was treated with DTNB, approximately    
4 µmol L1 of free thiol groups were modified by DTNB, 
consistent with the structure observation; however, no free 
thiol group was detected for the ATM-modified PKCζ-PB1. 
The results clearly suggest that ATM non-selectively blocks 
all four cysteine residues within the PKCζ-PB1 domain. 
Structurally, it is the steric effect caused by the modifica-
tion of a specific cysteine, Cys68, on the interface of 
PKCζ-PB1 that would inhibit its interaction with p62. We 
then generated a number of Cys68 mutations and examined 
their effect on the homotypic PB1-PB1 interaction between 
PKCζ and p62 in vitro (Figure 6C). Remarkably, mutating 
Cys68 to residues with bulky side chains (Tyr, Trp, Phe or 
Arg) led to complete loss of the PKCζ-p62 interaction, 
whereas substitution by Val (or Ile, data not shown), the 
corresponding residue(s) in other PB1 domains, had little 
effect. These data, together with previous results [38], indi-
cate that the conserved cysteine within the OPCA motif of 
aPKC-PB1 domains is the determinant for ATM inhibition 
of the interactions between aPKCs and other PB1-contain- 
ing proteins with a functional basic surface. 
ATM suppresses inflammation and retards bone erosion 
in arthritis and is capable of improving clinical conditions in 
a majority of patients, but the biological targets and the mo-
lecular mechanism of this drug are unclear [37,41,42]. The 
MAPK phosphatase-1, IB kinase, and thioredoxin reduc-
tase have been shown to be the target of ATM to regulate 
NF-B activation in different cell types, and the essential 
cysteine residues in their active sites have been proposed to 
be the ATM-modification sites [37,42,43]. ATM was re-
ported to disrupt PKCι-Par-6 interaction and inhibit 
non-small cell lung cancer growth and/or kill prostate can-
cer cells, which renders ATM a promising anticancer drug 
target [38–40,44]. We demonstrate here that ATM disrupts, 
through a similar mechanism, the p62-PKCζ interaction that 
is required for the biological functions of PKCζ in NF-B 
signaling [15,16]. Considering that dysfunction of NF-B 
has been linked to inflammatory, cancer, improper immune 
development and many other diseases, our data shed light 
on the molecular mechanism of ATM as a promising drug 
target for inflammation, autoimmune and cancer treatments. 
2.6  PKCζ-PB1 depolymerizes the p62-PB1 homo-  
oligomer 
As a well-defined type I/II PB1, p62-PB1 is characteristic of 
self-assembly in the same front-to-back manner through the 
two oppositely charged surfaces [18,31,34]. The thermody-
namics of p62-PB1 self-association was analyzed by ITC, 
with a Kd value of 8.93±0.94 nmol L
1, which is slightly 
lower than that for the p62-PKCζ heterodimer (Figure 7A). 
In the gel filtration assays, the wild-type p62-PB1 was elut-
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Figure 6  ATM-modified PKCζ-PB1 fails to interact with p62-PB1. A, Thermodynamic analysis of the interaction between PKCζ-PB1 and p62-PB1 by 
ITC. The top panels show heat release during titration of aliquots of p62-PB1AM into native (left) and ATM-modified (right) PKCζ-PB1, corrected for base-
line drift, and the bottom panels show the corresponding integrated heat of binding. B, Modification of native and ATM-modified PKCζ-PB1 (1 µmol L1) by 
DTNB (6.25 µmol L1). The modication process was monitored directly by absorbance measurements at 412 nm. SH, reactive thiol group. C, Effect of 
substituting Cys68 of PKCζ-PB1 with indicated amino acids on the PKCζ-p62 interaction. The GST-mediated pull-down assays were carried out using vari-
ous GST-PKCζ-PB1 mutants as indicated and p62-PB1AM. 
ed in the void volume, consistent with its nature of high- 
molecular-weight homo-oligomers (Figure 7B). To assess 
the impact of PKCζ-PB1 on oligomerization of the native 
p62-PB1, we coexpressed these two PB1 domains and 
found that the existence of PKCζ-PB1 converted the 
high-molecular-weight p62-PB1 polymer to complexes of 
lower order (Figure 7B). Furthermore, we generated a com-
plex between p62-PB1AM and p62-PB1BM to mimic the 
native p62-PB1 interaction, and its molecular weight was 
characterized to be ~30 kD, consistent with the calculated 
molecular mass of a p62-PB1 dimer (Figure 7B and C). We 
carried out competition assays between this complex and 
the GST-tagged PKCζ-PB1, which can be distinguished on 
the size exclusion chromatography. Due to the presence of a 
dimeric GST tag, the retention time of GST-PKCζ-PB1 
corresponded to an apparent molecular weight of ~70 kD, in 
reasonable agreement with its calculated dimeric molecular 
mass of 75 kD (Figure 7B and C). When the mixture of 
GST-PKCζ-PB1 and the p62-PB1 dimer was subjected to 
the gel filtration analysis, some of the p62-PB1AM proteins 
comigrated with PKCζ-PB1, which leaves some p62- 
PB1BM proteins in the uncomplexed, monomeric state 
(Figure 7B and C). Notably, the GST-mediated PKCζ-PB1 
dimer likely forms a tetramer with two molecules of p62- 
PB1AM, in agreement with our previous data of a 1:1 
complex between the non-tagged PKCζ-PB1 and p62- 
PB1AM (Figure 2C). Together, these data demonstrate that 
PKCζ-PB1 indeed disrupts the p62-PB1 homo-oligomer and 
concomitantly forms a front-to-back complex with p62-PB1, 
through interactions between the acidic OPCA motif of 
PKCζ-PB1 and the basic surface of p62-PB1. Evidences 
have indicated that loss of p62 homo-oligomerization af-
fects its cellular function, such as triggering the TRAF6- 
NF-B pathway [20]. Therefore, the depolymerization of 
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Figure 7  PKCζ-PB1 depolymerizes p62-PB1 homo-oligomer. A, Thermodynamic analysis of the p62 homo-oligomerization by ITC. The p62-PB1AM 
protein was titrated into a solution of p62-PB1BM. B, PKCζ converts the high-molecular-weight homo-assembly of p62 to a lower order in gel filtration 
analysis. C, PKCζ-PB1 disrupts the p62-PB1 homo-complex. GST-tagged PKCζ-PB1 was incubated with the pre-formed homo-complex of His6-p62- 
PB1AM and p62-PB1BM, and the mixture was analyzed by size exclusion chromatography. 
p62 homo-assembly by PKCζ might affect the formation 
and efficiency of the p62-TRAF6 signaling hubs that are 
critical for NF-B activation. Further investigations are re-
quired to elucidate the molecular mechanisms. 
In summary, we solved the crystal structure of PKCζ- 
PB1 in complex with the monomeric p62-PB1AM mutant, 
which affirms the front-to-back interaction between the 
acidic OPCA motif of one PB1 domain and the basic sur-
face from another PB1 domain (Figures 3 and 4). Notably, 
we identified an additional A3-B3 interface between PKCζ 
and p62 that may endow the specificity. Our detailed struc-
tural analyses suggest that the PB1 domains of both aPKC 
isoforms belong to the type I group, but not type I/II (Figure 
5). In addition, the gold-containing compound ATM can 
modify the conserved cysteine residue within the OPCA 
motif of the aPKC isoforms, which disrupts the interactions 
between p62 and PKCζ and might thus down-regulate the 
NF-B signaling (Figure 6). Interestingly, we also found 
that PKCζ-PB1 can attenuate the formation of high-     
molecular-weight p62-PB1 homo-oligomers, which might 
regulate the polyubiquitination of TRAF6 and subsequent 
activation of NF-B (Figure 7). Taken together, our struc-
tural and biochemical results provide the basis for develop-
ing inhibitors of the NF-B pathway, particularly the thi-
ol-reactive reagents that target the essential cysteine resi-
dues of aPKC isoforms. 
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